Background: A major obstacle faced by rare disease families is obtaining a genetic diagnosis. The average “diagnostic odyssey” lasts over five years, and causal variants are identified in under 50%. The Rare Genomes Project (RGP) is a direct-to-participant research study on the utility of genome sequencing (GS) for diagnosis and gene discovery. Families are consented for sharing of sequence and phenotype data with researchers, allowing development of a Critical Assessment of Genome Interpretation (CAGI) community challenge, placing variant prioritization models head-to-head in a real-life clinical diagnostic setting. Methods: Predictors were provided a dataset of phenotype terms and variant calls from GS of 175 RGP individuals (65 families), including 35 solved training set families, with causal variants specified, and 30 test set families (14 solved, 16 unsolved). The challenge tasked teams with identifying the causal variants in as many test set families as possible. Ranked variant predictions were submitted with estimated probability of causal relationship (EPCR) values. Model performance was determined by two metrics, a weighted score based on rank position of true positive causal variants and maximum F-measure, based on precision and recall of causal variants across EPCR thresholds. Results: Sixteen teams submitted predictions from 52 models, some with manual review incorporated. Top performing teams recalled the causal variants in up to 13 of 14 solved families by prioritizing high quality variant calls that were rare, predicted deleterious, segregating correctly, and consistent with reported phenotype. In unsolved families, newly discovered diagnostic variants were returned to two families following confirmatory RNA sequencing, and two prioritized novel disease gene candidates were entered into Matchmaker Exchange. In one example, RNA sequencing demonstrated aberrant splicing due to a deep intronic indel in ASNS , identified in trans with a frameshift variant, in an unsolved proband with phenotype overlap with asparagine synthetase deficiency. Conclusions: By objective assessment of variant predictions, we provide insights into current state-of-the-art algorithms and platforms for genome sequencing analysis for rare disease diagnosis and explore areas for future optimization. Identification of diagnostic variants in unsolved families promotes synergy between researchers with clinical and computational expertise as a means of advancing the field of clinical genome interpretation.
With an increasing amount of biological data available publicly, there is a need for a guide on how to successfully download and use this data. The 10 simple rules for using public biological data are: (1) use public data purposefully in your research; (2) evaluate data for your use case; (3) check data reuse requirements and embargoes; (4) be aware of ethics for data reuse; (5) plan for data storage and compute requirements; (6) know what you are downloading; (7) download programmatically and verify integrity; (8) properly cite data; (9) make reprocessed data and models Findable, Accessible, Interoperable, and Reusable (FAIR) and share; and (10) make pipelines and code FAIR and share. These rules are intended as a guide for researchers wanting to make use of available data and to increase data reuse and reproducibility.
23 October 2023 in Journal of Open Source Software
Quality Control (QC) of human genome sequencing and exome sequencing data is necessary to ensure they are of sufficient quality for downstream analyses. While several QC tools are available to measure quality parameters at various levels post-sequencing, their output needs to be reviewed and interpreted in a very manual and time-consuming process. Such manual review is a major challenge towards standardization and consistency, as the process can be subjective depending on the reviewer. To address these difficulties, we have developed QuaC, which implements, integrates, and standardizes QC best practices at our Center. It performs three major steps: (1) runs several QC tools using data produced by the read alignment (BAM) and small variant calling (VCF) as input and optionally accepts QC output for raw sequencing reads (FASTQ); (2) executes QuaC-Watch to perform QC checkup based on the expected thresholds for quality metrics; and (3) aggregates QC metrics produced by all the QC tools as well as QuaC-Watch results into single, self-contained MultiQC report, both at the per-sample and across-project levels. This report provides aggregate summaries for all samples within a project/cohort for efficient comprehensive review while still allowing for granular review down to individual metrics for a single sample. Finally, we have developed a "Sample QC review system" schema to standardize QC reviewer's logging of results and simplify downstream users' interpretation of the reviewers finding.
Accurate diagnosis for the 400 million people with rare diseases is critical for healthcare decisions, prognosis, understanding disease mechanisms, and identification of treatments. Despite advances in genome sequencing, barriers such as high interpretation costs, diagnostic expertise, throughput associated delays, and uncertain variant classifications persist, with demand exceeding capacity. Many variant classification methods focus narrowly on specific consequences, leading to the use of complex integrative pipelines that often overlook transcript variability and lack prediction transparency. To overcome these limitations, we introduce DITTO. This transparent, transcript-aware machine-learning method demonstrates superior overall performance in accuracy, recall, and precision when compared to existing tools. DITTO is publicly available at https://github.com/uab-cgds-worthey/DITTO
Prader-Willi syndrome (PWS) is a complex neurodevelopmental genetic disorder affecting multiple systems. We describe the design and feasibility of a fully remote, patient group-led, genome sequencing (GS) study that will evaluate the impact of genetic variants on the frequency and severity of PWS clinical symptoms, with responsible return of results. A total of 50 participants, or their legally authorized representative, provided consent via videoconference discussion and selected which genetic results would be returned. Participants were sent dried blood spot cards for GS and a buccal swab kit for orthogonal pharmacogenomics analysis. A subset of legally authorized representative LARs participated in semistructured interviews about their GS experience. All 50 participants completed the study and elected to receive their primary findings, and 48 of 49 participants who consented to receive pharmacogenomic information returned the buccal swab kit. Forty-seven participants consented to receive secondary findings per current American College of Medical Genetics guidelines; 2 had actionable results, with online genetic counseling support provided. Three families received medically significant findings related to variants associated with blood clot formation, which is important because individuals with PWS are at an increased risk for thrombotic events. Interview participants expressed a high degree of interest in the findings and emphasized the ease of participating in the study but felt the process was lengthy. A fully remote GS study is feasible to perform within a rare disease population, and responsibly returning genetic findings that are important to families is achievable.